JP7657807B2 - 三環式テトラヒドロイソキノリン誘導体、その調製方法及びその医薬的応用 - Google Patents

三環式テトラヒドロイソキノリン誘導体、その調製方法及びその医薬的応用 Download PDF

Info

Publication number
JP7657807B2
JP7657807B2 JP2022540980A JP2022540980A JP7657807B2 JP 7657807 B2 JP7657807 B2 JP 7657807B2 JP 2022540980 A JP2022540980 A JP 2022540980A JP 2022540980 A JP2022540980 A JP 2022540980A JP 7657807 B2 JP7657807 B2 JP 7657807B2
Authority
JP
Japan
Prior art keywords
group
general formula
compound
groups
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022540980A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023509944A5 (https=
JP2023509944A (ja
Inventor
方龍 楊
興 樊
晶晶 嚴
曦倩 張
峰 賀
維康 陶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Shanghai Hengrui Pharmaceutical Co Ltd
Publication of JP2023509944A publication Critical patent/JP2023509944A/ja
Publication of JP2023509944A5 publication Critical patent/JP2023509944A5/ja
Application granted granted Critical
Publication of JP7657807B2 publication Critical patent/JP7657807B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0834—Compounds having one or more O-Si linkage
    • C07F7/0836—Compounds with one or more Si-OH or Si-O-metal linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022540980A 2020-01-10 2021-01-08 三環式テトラヒドロイソキノリン誘導体、その調製方法及びその医薬的応用 Active JP7657807B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
CN202010025118 2020-01-10
CN202010025118.5 2020-01-10
CN202010036802 2020-01-14
CN202010036802.3 2020-01-14
CN202010273891 2020-04-09
CN202010273891.3 2020-04-09
CN202010680491 2020-07-15
CN202010680491.4 2020-07-15
CN202010819555 2020-08-14
CN202010819555.4 2020-08-14
CN202010971693 2020-09-16
CN202010971693.4 2020-09-16
PCT/CN2021/070826 WO2021139756A1 (zh) 2020-01-10 2021-01-08 三环四氢异喹啉类衍生物、其制备方法及其在医药上的应用

Publications (3)

Publication Number Publication Date
JP2023509944A JP2023509944A (ja) 2023-03-10
JP2023509944A5 JP2023509944A5 (https=) 2024-01-17
JP7657807B2 true JP7657807B2 (ja) 2025-04-07

Family

ID=76787742

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022540980A Active JP7657807B2 (ja) 2020-01-10 2021-01-08 三環式テトラヒドロイソキノリン誘導体、その調製方法及びその医薬的応用

Country Status (11)

Country Link
US (1) US12428428B2 (https=)
EP (1) EP4089094A4 (https=)
JP (1) JP7657807B2 (https=)
KR (1) KR20220125272A (https=)
CN (2) CN114746424B (https=)
AU (1) AU2021205156A1 (https=)
BR (1) BR112022013322A2 (https=)
CA (1) CA3164166A1 (https=)
MX (1) MX2022008091A (https=)
TW (1) TWI882060B (https=)
WO (1) WO2021139756A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114746424B (zh) 2020-01-10 2023-06-16 江苏恒瑞医药股份有限公司 三环四氢异喹啉类衍生物、其制备方法及其在医药上的应用
AU2022307207A1 (en) * 2021-07-09 2024-02-15 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Salt types of tricyclic tetrahydro isoquinoline derivative
TW202317539A (zh) 2021-07-15 2023-05-01 大陸商四川海思科製藥有限公司 芳氨基衍生物雌激素受體調節劑及其用途
EP4584257A1 (en) 2022-09-09 2025-07-16 Sanofi Substituted tetrahydrocyclohepta[e]indole derivatives, processes for their preparation and therapeutic uses thereof
TW202547495A (zh) * 2024-04-01 2025-12-16 大陸商山東盛迪醫藥有限公司 一種選擇性雌激素受體降解劑的製備方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018521988A (ja) 2015-06-16 2018-08-09 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． ピペリジン誘導体およびその製造方法および医薬用途
JP2019510799A (ja) 2016-04-08 2019-04-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト テトラヒドロイソキノリン エストロゲン受容体モジュレーター及びその使用
WO2019228443A1 (en) 2018-05-30 2019-12-05 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Selective estrogen receptor downregulators and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1113007A1 (en) 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
JP2010514695A (ja) 2006-12-21 2010-05-06 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物および方法およびそのための適応症
WO2013073875A1 (ko) 2011-11-15 2013-05-23 한국화학연구원 신규한 항바이러스성 피롤로피리딘 유도체 및 이의 제조방법
US20150336977A1 (en) 2013-01-07 2015-11-26 B.G. Negev Technologies And Applications Ltd. Coumestan, Coumestrol, Coumestan Derivatives and Processes of Making the Same and Uses of Same
WO2014141292A2 (en) 2013-03-04 2014-09-18 Intas Pharmaceuticals Limited Endoxifen citrate polymorph and process for preparing the same
IN2013MU00665A (https=) 2013-03-05 2015-07-03 Cipla Ltd
MX2015011132A (es) 2013-03-14 2015-11-30 Seragon Pharmaceuticals Inc Moduladores policiclicos del receptor de estrogenos y sus usos.
JP2016522167A (ja) 2013-04-04 2016-07-28 ジ アドミニストレーターズ オブ ザ トゥレーン エデュケーショナル ファンド ヒト間葉系幹細胞に対するダイゼイン類似体の骨形成活性の向上
UY35590A (es) 2013-05-28 2014-11-28 Astrazeneca Ab Nuevos compuestos para el tratamiento del cáncer
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
EP3328999B1 (en) 2015-07-30 2020-03-25 Arcis Biotechnology Holdings Limited Method using a quaternary ammonium compound
EP3640251B1 (en) 2016-10-24 2021-12-08 Astrazeneca AB 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
WO2018130124A1 (zh) * 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的三环类化合物及其应用
WO2019002442A1 (en) 2017-06-29 2019-01-03 Astrazeneca Ab CHEMICAL COMPOUNDS
NZ764463A (en) 2017-11-14 2023-07-28 Kind Pharmaceutical Heterocyclic compound and application thereof in medicine
CN111770924B (zh) 2018-04-04 2023-05-09 深圳福沃药业有限公司 用于治疗乳腺癌的雌激素受体降解剂
CN114746424B (zh) 2020-01-10 2023-06-16 江苏恒瑞医药股份有限公司 三环四氢异喹啉类衍生物、其制备方法及其在医药上的应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018521988A (ja) 2015-06-16 2018-08-09 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． ピペリジン誘導体およびその製造方法および医薬用途
JP2019510799A (ja) 2016-04-08 2019-04-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト テトラヒドロイソキノリン エストロゲン受容体モジュレーター及びその使用
WO2019228443A1 (en) 2018-05-30 2019-12-05 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Selective estrogen receptor downregulators and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Database REGISTRY，2003年，RN 767249-50-3、RN 600117-24-6、RN 600117-23-5、RN 596790-58-8、RN 596790-57-7、Retrieved from STN international [online] ;retrieved on 22 October 2024

Also Published As

Publication number Publication date
TW202140495A (zh) 2021-11-01
US12428428B2 (en) 2025-09-30
JP2023509944A (ja) 2023-03-10
EP4089094A1 (en) 2022-11-16
CN114746424B (zh) 2023-06-16
CA3164166A1 (en) 2021-07-15
CN114746424A (zh) 2022-07-12
TWI882060B (zh) 2025-05-01
CN116731064A (zh) 2023-09-12
BR112022013322A2 (pt) 2022-09-20
KR20220125272A (ko) 2022-09-14
WO2021139756A1 (zh) 2021-07-15
AU2021205156A1 (en) 2022-07-14
MX2022008091A (es) 2022-07-11
EP4089094A4 (en) 2023-08-02
US20230140679A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
JP7657807B2 (ja) 三環式テトラヒドロイソキノリン誘導体、その調製方法及びその医薬的応用
JP7813970B2 (ja) 縮合イミダゾール誘導体、その調製方法及びその医薬的応用
CN109219604B (zh) 四氢异喹啉雌激素受体调节剂及其用途
CN109311876B (zh) 杂芳基雌激素受体调节剂及其用途
JP2026053592A (ja) 縮合イミダゾール誘導体、その調製方法及びその医薬的応用
EP4043459A1 (en) Substituted tricyclic compound as prmt5 inhibitor and use thereof
CN112375077A (zh) 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
JP2023528925A (ja) ピリドンピリミジン系誘導体、その調製方法及びその医薬的応用
JP7720906B2 (ja) ピロリジン化合物及びその使用
JP2018536658A (ja) テトラヒドロナフタレンエストロゲン受容体モジュレーター及びその使用
TW202003495A (zh) 苯並哌啶或雜芳基並哌啶類衍生物、其製備方法及其在醫藥上的應用
CN111499614A (zh) 四氢异喹啉类衍生物、其制备方法及其在医药上的应用
TWI858082B (zh) 吲唑類衍生物、其製備方法及其在醫藥上的應用
RU2830109C1 (ru) Трициклическое тетрагидроизохинолиновое производное, способ его получения и его применение в медицине
HK40076301A (en) Tricyclic tetrahydroisoquinoline derivative, preparation method therefor and application thereof in medicine
HK40076301B (zh) 三环四氢异喹啉类衍生物、其制备方法及其在医药上的应用
HK40064838A (en) Indazole derivative, preparation method therefor, and pharmaceutical application thereof
HK40064838B (zh) 吲唑类衍生物、其制备方法及其在医药上的应用
EP4495119A1 (en) Fused heterocyclic compound, and preparation method therefor and medical use thereof
CN120981467A (zh) 一种egfr突变抑制剂及其应用
HK40041466A (en) Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
HK40041467A (en) Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
HK40003989A (en) Heteroaryl estrogen receptor modulators and uses thereof
HK40003989B (en) Heteroaryl estrogen receptor modulators and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240105

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240315

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250318

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250326

R150 Certificate of patent or registration of utility model

Ref document number: 7657807

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150